Two New TRU™ Brand Rapid Tests for the Detection of Epstein-Barr Virus
go back to news archives| Meridian Bioscience, Inc. has announced the launch of two new rapid tests for Epstein-Barr Virus (EBV): TRU EBV-M™ and TRU EBV-G™. The TRU EBV tests are the first rapid tests on the market which employ recombinant antigen technology to detect IgM and IgG antibodies specific to EBV. EBV is the primary cause of infectious mononucleosis and has been implicated in a number of benign and malignant disorders, including Hodgkin's disease and certain lymphomas. According to the Centers for Disease Control and Prevention (CDC), as many as 95% of adults ages 35-40 have been infected with EBV. The current rapid methods for the diagnosis of infectious mononucleosis rely primarily on the patient's symptoms and non-specific heterophile antibody testing. The TRU EBV tests, however, are highly sensitive for specific antibodies that can classify acute and chronic stages of the disease. The TRU EBV test system is a simple, sensitive and rapid approach that allows healthcare providers to more precisely diagnose EBV infections. |
NOTE: This item is from our 'historic' database and
may contain information which is not up to date.
Source : Meridian Bioscience, Inc. View Company Information
Posted on April 15, 2008
advertisement
advertisement
advertisement
advertisement
LATEST MICROBIOLOGY NEWS
MICROBIOLOGY EVENTS
-
USP Chapter <86> and the Move to Recombinant Methods
-
2025 Novogene Sequencing Symposium
-
Explore the Future of Sterility Testing with Rapid Micro Biosystems®
-
Understanding USP <73> to Accelerate Sterility Testing for Short-Life Products
-
British Society For Microbial Technology 40th Anniversary Microbiology Conference
-
How Is VIDAS® KUBE™ Transforming Food Pathogen Detection?
-
Sampling and Microbial Testing of Water and Data Trending
-
European Microbiology Conference and Workshop 2025
-
Future Labs Live 2025
-
2025 Endotoxin Testing Summit
